Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials

BACKGROUND: Two phase 3 trials compared 28–35 days of treatment with oral dabigatran 220 mg or 150 mg (RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for prevention of venous thromboembolism (VTE) after elective total hip arthroplasty. METHODS: This pres...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Thromb J
मुख्य लेखकों: Eriksson, Bengt I., Dahl, Ola E., Rosencher, Nadia, Clemens, Andreas, Hantel, Stefan, Feuring, Martin, Kreuzer, Jörg, Huo, Michael, Friedman, Richard J.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2015
विषय:
Original Clinical Investigation
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4647514/
https://ncbi.nlm.nih.gov/pubmed/26578849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-015-0067-8
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन